Loading chat...
GA HB1107
Bill
Status
Introduced
3/3/2014
Primary Sponsor
Sharon Cooper
Click for details
AI Summary
- Establishes a state-wide expanded access clinical trial program, subject to FDA approval, for the use of cannabidiol (CBD) to treat pediatric patients up to age 21 with severe, refractory forms of epilepsy that do not respond to standard medications
- Defines cannabidiol as a preparation containing at least 98% CBD and no more than 0.30% THC, sourced only from FDA-approved providers that have completed animal safety testing
- Limits principal investigators and subinvestigators to board certified pediatric neurologists practicing at academic medical centers in Georgia, who must obtain FDA approval, a DEA license, and a Georgia Board of Pharmacy permit
- Requires the principal investigator to submit an annual executive summary of clinical trial results, with patient names redacted, to the chairpersons of the House and Senate Health and Human Services Committees
- Explicitly prohibits the cultivation or processing of marijuana, cannabis, or hemp in Georgia under this act and requires no state appropriations for implementation
Legislative Description
Therapeutic Cannabidiol Act of 2014; enact
Last Action
House Second Readers
3/5/2014
Full Bill Text
No bill text available